UBS analyst Joshua Spector downgrades Corteva (NYSE:CTVA) from Buy to Neutral and raises the price target from $70 to $73.
Amazon CFO Says Company Sees Step Down in Revenue Growth Continuing For Next Few Quarters
-Reuters Citing Media Call
UBS Downgrades Corteva to Neutral, Raises Price Target to $73
UBS analyst Joshua Spector downgrades Corteva (NYSE:CTVA) from Buy to Neutral and raises the price target from $70 to $73.
Related Posts
Neptune Wellness Reports Third Consecutive Quarter Of QoQ Revenue Growth, Unveils Action Plan
Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT) published its financial and operating results late Monday for the three months ended on September 30, revealing that it has generated $15.7 million in the second quarter of fiscal 2022, up by 27% sequentially.
Trump-Established Bitcoin Reserve And ‘Digital Asset Stockpile’ May Be Underwater
The “strategic national digital assets stockpile” established by the Trump administration is likely facing unrealized losses, a new report shows.
Akamai Is Ready To Gain From Shift To Cloud, Synergies From Guardicore And Linode Acquisitions, Analysts Say
Keybanc analyst Thomas Blakey maintained Akamai Technologies, Inc (NASDAQ: AKAM) with an Overweight and cut the